Results 31 to 40 of about 11,979 (257)

Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy

Frontiers in Immunology, 2023
Every type of cancer tissue is theoretically more vulnerable to viral infection. This natural proclivity has been harnessed as a new anti-cancer therapy by employing oncolytic viruses (OVs) to selectively infect and destroy cancer cells while providing ...
Matin Ghasemi, Laleh Abbasi, Leila Ghanbari Naeini, Pajman Kokabian, Najmeh Nameh Goshay Fard, Nozar Givtaj   +5 more
semanticscholar   +1 more source

Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study

Frontiers in Immunology, 2022
Background Central nervous system tumor (CNST) is one of the most complicated and lethal forms of human tumors with very limited treatment options. In recent years, growing evidence indicates that oncolytic virotherapy (OVT) has emerged as a promising ...
Kunming Cheng, Huan Zhang, Q. Guo, P. Zhai, Yan Zhou, Weiguang Yang, Yulin Wang, Yanqiu Lu, Zefeng Shen, Haiyang Wu   +9 more
semanticscholar   +1 more source

Magnetic‐Powered Janus Cell Robots Loaded with Oncolytic Adenovirus for Active and Targeted Virotherapy of Bladder Cancer

Advances in Materials, 2022
A unique robotic medical platform is designed by utilizing cell robots as the active “Trojan horse” of oncolytic adenovirus (OA), capable of tumor‐selective binding and killing.
Z. Cong, Songsong Tang, Leiming Xie, Ming Yang, Yangyang Li, Dongdong Lu, Jiahong Li, Qin-Zheng Yang, Qiwei Chen, Zhiqiang Zhang, Xueji Zhang, Song Wu   +11 more
semanticscholar   +1 more source

Oncolytic Virotherapy with Myxoma Virus [PDF]

Journal of Clinical Medicine, 2020
Oncolytic viruses are one of the most promising novel therapeutics for malignant cancers. They selectively infect and kill cancer cells while sparing the normal counterparts, expose cancer- specific antigens and activate the host immune system against both viral and tumor determinants.
Masmudur M. Rahman, Grant McFadden
openaire   +3 more sources

Personalized virotherapy in cancer

Aging, 2015
After decades of intensive research, pancreatic adenocarcinoma (PDAC) remains a highly lethal disease with a median survival time that does not exceed 6.5 months [1]. Since more than 80% of patients present with advanced metastatic disease, systemic chemotherapy remains the only treatment.
Cafferata Eduardo G, Podhajcer, Osvaldo Luis   +1 more
openaire   +4 more sources

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

Frontiers in Immunology, 2021
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them.
Victor Cervera-Carrascon, Victor Cervera-Carrascon, Dafne C. A. Quixabeira, Joao M. Santos, Joao M. Santos, Riikka Havunen, Riikka Havunen, Ioanna Milenova, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan J. Garcia-Vallejo, Victor W. van Beusechem, Tanja D. de Gruijl, Aino Kalervo, Suvi Sorsa, Anna Kanerva, Anna Kanerva, Akseli Hemminki, Akseli Hemminki, Akseli Hemminki   +21 more
doaj   +1 more source

An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer. [PDF]

Vaccines (Basel)
Intratumoural oncolytic virotherapy may have promise as a means to debulk and downstage inoperable tumours in preparation for successful surgery. Here, we describe the unique case of a 50-year-old self-experimenting female virologist with locally ...
Forčić D, Mršić K, Perić-Balja M, Kurtović T, Ramić S, Silovski T, Pedišić I, Milas I, Halassy B.   +8 more
europepmc   +2 more sources

Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword

International Journal of Molecular Sciences, 2022
Oncolytic virotherapy is a rapidly progressing field that uses oncolytic viruses (OVs) to selectively infect malignant cells and cause an antitumor response through direct oncolysis and stimulation of the immune system.
Sarah E. Blitz, A. Kappel, F. Gessler, Neil V. Klinger, Omar Arnaout, Yi Lu, Pierpaolo Peruzzi, Timothy R. Smith, E. Chiocca, G. Friedman, J. Bernstock   +10 more
semanticscholar   +1 more source

Oncolytic virotherapy for ovarian cancer [PDF]

Oncolytic Virotherapy, 2012
In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies.
Li, Shoudong, Tong, Jessica, Rahman, Masmudur M., Shepherd, Trevor G., McFadden, Grant   +4 more
openaire   +6 more sources

The use of oncolytic virotherapy in the neoadjuvant setting

Journal for ImmunoTherapy of Cancer, 2022
Surgical removal of tumors remains a front-line therapy for many types of cancer. However, this treatment often fails to eradicate disease due to either recurrence of the original tumor or development of distant micrometastases.
Raquela J. Thomas, E. Bartee
semanticscholar   +1 more source